Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSHA Taysha Gene Therapies, Inc.

Market Closed 04-24 16:00:00 EDT

6.40

+0.00

0.00%

盘后6.40

+0.000.00%

17:50 EDT

High6.47	Low6.24	Vol1.93M
Open6.42	D1 Closing6.40	Amplitude3.52%
Mkt Cap1.84B	Tradable Cap1.18B	Total Shares287.27M
T/O12.26M	T/O Rate1.04%	Tradable Shares185.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":6.4,"timestamp":1777060800000,"preClose":6.4,"halted":0,"volume":1928064,"hourTrading":{"tag":"盘后","latestPrice":6.4,"preClose":6.4,"latestTime":"17:50 EDT","volume":78092,"amount":499788.3,"timestamp":1777067414062,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":185000000,"shares":287269885,"eps":-0.340916,"marketStatus":"Market Closed","change":0,"latestTime":"04-24 16:00:00 EDT","open":6.42,"high":6.465,"low":6.24,"amount":12263192.711424,"amplitude":0.035156,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.340916,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":6.4,"preHourTrading":{"tag":"盘前","latestPrice":6.4,"preClose":6.4,"latestTime":"09:25 EDT","volume":1439,"amount":9112.166749,"timestamp":1777037100008,"change":0,"changeRate":0,"amplitude":0.041172},"postHourTrading":{"tag":"盘后","latestPrice":6.4,"preClose":6.4,"latestTime":"17:50 EDT","volume":78092,"amount":499788.3,"timestamp":1777067414062,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5806887964567963,"impliedVol":1.1043,"impliedVolPercentile":0.6693},"requestUrl":"/m/hq/s/TSHA","defaultTab":"news","newsList":[{"id":"2629045063","title":"Taysha Gene Therapies announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629045063","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629045063?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:03","pubTimestamp":1776859428,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies schedules annual stockholder meeting for June 1, 2026, to be held virtually.Ballot includes election of two Class III director nominees to terms ending at 2029 annual meeting.Advisory votes cover named executive officer compensation, plus preferred frequency of future say-on-pay votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL592pj0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627214080","title":"Unusually active option classes on open April 16th","url":"https://stock-news.laohu8.com/highlight/detail?id=2627214080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627214080?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:12","pubTimestamp":1776352334,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Taysha Gene Therapies (TSHA), Energy Vault Holdings (NRGV), New Era Energy & Digital Inc (NUAI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-16th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-16th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRGV","BK4139","BK4561","BK4182","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230353","title":"U.S. Small Caps Finish Mixed As Taysha Gene Therapies Leads, BRP Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230353","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230353?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:21","pubTimestamp":1776284460,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Wednesday, as the Russell 2000 Index increased 0.3%, while the S&P Small Cap 600 Index was down 0.1%.Among companies with a market value of $1 billion to $6.7 billion, Taysha Gene Therapies Inc. was the best performer during the session, surging 27%, followed by Nexa Resources S.A., which surged 23%. D-Wave Quantum Inc. shares surged 23%, Maase Inc. surged 17%, and shares of Quantum Computing Inc. surged 16%.BRP Inc. was the biggest laggard, dropping 35%, followed by shares of Polaris Inc., which dropped 17%. Shares of Polibeli Group Ltd. dropped 16%, SolarEdge Technologies Inc. shares plunged 12%, and Intercorp Financial Services Inc. tumbled 11%.Major stock indexes in the U.S. ended Wednesday mixed as the Nasdaq Composite Index gained 1.6%. Meanwhile, the S&P 500 Index gained 0.8%, and the Dow Jones Industrial Average declined 0.1%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627284517","title":"Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2627284517","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627284517?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:16","pubTimestamp":1776255401,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum has maintained their bullish stance on TSHA stock, giving a Buy rating on April 6. Gil Blum has given his Buy rating due t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-taysha-gene-therapies-driven-by-strong-leadership-strategic-positioning-and-attractive-risk‑reward-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-taysha-gene-therapies-driven-by-strong-leadership-strategic-positioning-and-attractive-risk‑reward-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627656404","title":"Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2627656404","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627656404?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:34","pubTimestamp":1776112484,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies director, President and Head of R&D Sukumar Nagendran sold 200,000 shares on April 10, 2026 at USD 4.46.He exercised stock options for 19,021 shares on April 10, 2026 at USD 1.71.Directly held common stock position stood at 1,136,410 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL9gDwJs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625839670","title":"Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2625839670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625839670?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:26","pubTimestamp":1775489160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 11:26 ET (15:26 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676605","title":"Taysha Gene Therapies price target raised to $17 from $14 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676605","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676605?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:09","pubTimestamp":1775473784,"startTime":"0","endTime":"0","summary":"Canaccord analyst Whitney Ijem raised the firm’s price target on Taysha Gene Therapies (TSHA) to $17 from $14 and keeps a Buy rating on the shares....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-price-target-raised-to-17-from-14-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-price-target-raised-to-17-from-14-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624578036","title":"Taysha grants 300,000 RSUs under Nasdaq inducement plan for new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2624578036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624578036?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:00","pubTimestamp":1775217622,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies granted inducement equity awards to four new employees under its 2023 Inducement Plan.Awards included restricted stock units covering 300,000 shares.Stock options covered 92,400 shares with an exercise price of $4.31.RSUs vest in four equal annual installments starting on first anniversary of vesting commencement date.Options vest over four years, with 25% vesting on first anniversary.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL68sYzf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","NDAQ","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4112","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657963","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657963","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657963?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:00","pubTimestamp":1775217600,"startTime":"0","endTime":"0","summary":"DALLAS, April  03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/03/3267992/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","CNS","BK4135","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187246058","title":"Stock Track | Taysha Gene Therapies Soars 5.33% Intraday After Cantor Fitzgerald Issues Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1187246058","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187246058?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445547,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (TSHA) saw its stock price soar by 5.33% during intraday trading on Wednesday, following a positive analyst update.The surge appears to be driven by Cantor Fitzgerald...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622107533","title":"Taysha Gene Therapies (TSHA) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107533?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:18","pubTimestamp":1774441094,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Taysha Gene Therapies, with a price target of $19....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-cantor-fitzgerald-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-cantor-fitzgerald-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621744140","title":"Should Rett Breakthrough Status and Pivotal Trial Progress Require Action From Taysha Gene Therapies (TSHA) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744140","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744140?lang=en_us&edition=fundamental","pubTime":"2026-03-23 05:08","pubTimestamp":1774213734,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies reported full-year 2025 results on March 19, 2026, posting US$9.77 million in sales versus US$8.33 million a year earlier, alongside a net loss of US$109 million and appointing Brad Martin as Senior Vice President, Market Access and Value in February 2026.\nAt the same time, the company highlighted clinical and regulatory progress for its Rett syndrome program TSHA-102, including FDA Breakthrough Therapy designation, written FDA alignment on pivotal trial design and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/should-rett-breakthrough-status-and-pivotal-trial-progress-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/should-rett-breakthrough-status-and-pivotal-trial-progress-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU2065732104.USD","BK4097","ISBC","PRGS","TSHA","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621717175","title":"Taysha Gene Therapies (TSHA) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2621717175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621717175?lang=en_us&edition=fundamental","pubTime":"2026-03-22 21:15","pubTimestamp":1774185309,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Yanan Zhu maintained a Buy rating on Taysha Gene Therapies on March 20 and set a price target of $11.00. The company’s shares c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0149725797.USD","LU1363072403.SGD","LU0320765489.SGD","LU1267930490.SGD","LU2236285917.USD","LU0289960550.SGD","LU1894683348.USD","IE00B19Z3581.USD","LU0942090050.USD","LU0742534661.SGD","LU0162691827.USD","LU0708994859.HKD","LU2461242641.AUD","LU0048573561.USD","BK4207","LU0072461881.USD","LU0787776722.HKD","LU1894683264.USD","IE00B19Z3B42.SGD","BK4588","LU0128525929.USD","LU1814569148.SGD","BK4501","IE0002270589.USD","LU0029864427.USD","LU0130102774.USD","TSHA","LU1267930227.SGD","LU0314106906.USD","LU1069347547.HKD","IE00B7SZLL34.SGD","LU0267386448.USD","BK4559","LU0211327993.USD","LU1201861249.SGD","BK4139","LU0648001328.SGD","LU0070302665.USD","LU1668664300.SGD","LU0106831901.USD","LU0251142724.SGD","LU0251131958.USD","BK4504","LU0868494617.USD","LU0256863811.USD","LU0868494708.USD","LU0052756011.USD","LU1035773651.USD","LU1267930573.SGD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621874791","title":"Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2621874791","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621874791?lang=en_us&edition=fundamental","pubTime":"2026-03-22 03:09","pubTimestamp":1774120199,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (NasdaqGS:TSHA) received FDA Breakthrough Therapy designation for TSHA-102 in Rett syndrome.\nThe company reported a 100% patient response rate in pivotal Phase I/II data for TSHA-102.\nRegulators aligned with Taysha on pivotal trial designs for its lead Rett syndrome program.\nTaysha added a key commercial hire as it prepares for potential TSHA-102 commercialization.\n\nTaysha Gene Therapies, trading at $4.4 per share, has been drawing attention as its 1 year return stands...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-advances-rett-program-as-valuation-dra","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-advances-rett-program-as-valuation-dra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620270120","title":"Taysha Gene Therapies Signals Momentum in Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620270120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620270120?lang=en_us&edition=fundamental","pubTime":"2026-03-20 08:02","pubTimestamp":1773964974,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (($TSHA)) has held its Q4 earnings call. Read on for the main highlights of the call. Taysha Gene Therapies’ latest ear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-signals-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-signals-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620914273","title":"Taysha Gene Therapies Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620914273","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620914273?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:38","pubTimestamp":1773945480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 14:38 ET (18:38 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620273943","title":"Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620273943?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:30","pubTimestamp":1773945007,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Taysha Gene Ther...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-collegium-pharmaceutical-coll-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-collegium-pharmaceutical-coll-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","BK4585","COLL","BK4581","BK4139","BLSX","XBI","BK4007","TSHA","LU0128526141.USD","BLSG","BK4137","LU0029874061.USD","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620278122","title":"Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620278122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620278122?lang=en_us&edition=fundamental","pubTime":"2026-03-20 01:55","pubTimestamp":1773942908,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Geulah Livshits maintained a Buy rating on Taysha Gene Therapies today and set a price target of $12.00. According to TipRa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620274225","title":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620274225","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620274225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:31","pubTimestamp":1773927096,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings SummaryTaysha Gene Therapies Inc TSHA.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL8N4071MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162677975","title":"Stock Track | Taysha Gene Therapies Soars 6.52% in Pre-market on Earnings Beat and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1162677975","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162677975?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:38","pubTimestamp":1773923933,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.3974},{"period":"3month","weight":0.3734},{"period":"6month","weight":0.3474},{"period":"1year","weight":2.5165},{"period":"ytd","weight":0.1636}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.177745},{"month":2,"riseRate":0.5,"avgChangeRate":0.091899},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104956},{"month":4,"riseRate":0.5,"avgChangeRate":0.079764},{"month":5,"riseRate":0.4,"avgChangeRate":0.055742},{"month":6,"riseRate":0.2,"avgChangeRate":-0.029545},{"month":7,"riseRate":0.6,"avgChangeRate":0.019307},{"month":8,"riseRate":0.8,"avgChangeRate":0.75256},{"month":9,"riseRate":0.2,"avgChangeRate":-0.089587},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.04036},{"month":11,"riseRate":0.5,"avgChangeRate":0.137875},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.034429}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction